{"disease":{"id":"advanced-cancers","name":"advanced cancers"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06825715","title":"Multilevel Intervention for Precision Oncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":2653,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT02160366","title":"Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04141397","title":"Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT05356741","title":"To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":645,"lead_sponsor_name":"Vir Biotechnology, Inc.","has_results":false},{"nct_id":"NCT01880359","title":"AF CRT +/- Nimorazole in HNSCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":640,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03967938","title":"Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":540,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT04524871","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":518,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02437617","title":"Genomic Profiling Assay in Phase I","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06799637","title":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT06360354","title":"A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":322,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07238075","title":"ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"Adcytherix SAS","has_results":false},{"nct_id":"NCT03386721","title":"Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":256,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01389830","title":"End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":230,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02558257","title":"Perception of Palliative Care Encounter","phase":"","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT01375114","title":"The Effects of Ginseng on Cancer-Related Fatigue","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":165,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03512340","title":"Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Surface Oncology","has_results":false},{"nct_id":"NCT01266057","title":"Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02523378","title":"Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion","phase":"NA","overall_status":"COMPLETED","enrollment_count":138,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05639751","title":"PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT05838768","title":"Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":123,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01213238","title":"Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07092748","title":"A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Zhejiang Hisun Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT02801045","title":"Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient","phase":"NA","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT07326137","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","phase":"","overall_status":"RECRUITING","enrollment_count":103,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03872206","title":"Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT02521194","title":"Occupational Therapy in Palliative Care","phase":"NA","overall_status":"TERMINATED","enrollment_count":86,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06678659","title":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Recursion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT02459964","title":"Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02408861","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06715241","title":"A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":77,"lead_sponsor_name":"ARCAGY/ GINECO GROUP","has_results":false},{"nct_id":"NCT01952847","title":"Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":77,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02042989","title":"MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01563302","title":"Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT01430572","title":"Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01983969","title":"Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06893380","title":"Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":61,"lead_sponsor_name":"CHA University","has_results":false},{"nct_id":"NCT02422329","title":"Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention","phase":"NA","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06343272","title":"Lymphocyte Enhancement in Gastroenteric Oncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03956680","title":"An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01021072","title":"A First in Man Study of MABp1 in Patients With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02597478","title":"Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05098197","title":"A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT07244965","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT07003022","title":"Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fudan University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}